NZ332404A - use of a controlled release formulation containing a polypeptide such as IL-6R encapsulated in alginate for treating inflammatory bowel disease
- Google Patents
use of a controlled release formulation containing a polypeptide such as IL-6R encapsulated in alginate for treating inflammatory bowel disease
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex CorpfiledCriticalImmunex Corp
Priority claimed from NZ288997Aexternal-prioritypatent/NZ288997A/en
Publication of NZ332404ApublicationCriticalpatent/NZ332404A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
A polypeptide being either tumour necrosis factor receptor (TNFR), interleukin-1 receptor (IL-1R), interleukin-1 receptor antagonist (IL-1ra) or interleukin-6 receptor (IL-6R) or a monoclonal antibody that is immunoreactive against TNF, IL-6 or IL-1is used in the manufacture of a medicament to treat inflammatory bowel disease. The medicament is in the form of a controlled release formulation and the polypeptide is encapsulated in alginate.
NZ332404A1994-06-241995-06-22use of a controlled release formulation containing a polypeptide such as IL-6R encapsulated in alginate for treating inflammatory bowel disease
NZ332404A
(en)
Preparation of specific antibodies against murine IL-1ra and the establishment of IL-1ra as an endogenous regulator of bacteria-induced fulminant hepatitis in mice
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
Intravenous immunoglobulin treatment in women with recurrent abortions: increased cytokine levels and reduced Th1/Th2 lymphocyte ratio in peripheral blood
High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.